Radar · Life Sciences in Massachusetts
Best Life Sciences Companies in Massachusetts, United States
The 2066 best Life Sciences companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Moderna.
By Riya SenguptaFinancials
2066companies tracked
$89.6Bdisclosed funding
10unicorns
1281have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × MASSACHUSETTS
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
1.3Mcombined LinkedIn audience
68%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Moderna Developer of mRNA-based therapeutics for a wide range of diseases 82Tech top 11%Funding top 15%Market top 22%Partners top 25% All 12 signals ▾Techtop 11% Fundingtop 15% Markettop 22% Partnerstop 25% Talenttop 25% Newstop 31% Moattop 32% Patentstop 34% Globaltop 38% Innovationtop 39% Growthbottom 49% Fin. healthbottom 48% Tech: 57 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Ses Funding: Raised $2.8B across 20 rounds · 20 rounds over 14 yrs (1.4/yr) rank vs industry peers · Fliar Intelligence Index 82/100 | $2.8B | 17 mo ago | 1,312 | Robert Langer Co-Founder | Apple iCloud MailMicrosoft 365TypeScript+24 | 31 patents Patents concentrated in health & consumer products | 1 internship |
| 2 | XtalPi 🦄 AI-based drug research and development company 64Funding top 18%AI top 26%Talent top 28%Patents top 31% All 13 signals ▾Fundingtop 18% AItop 26% Talenttop 28% Patentstop 31% Moattop 31% Innovationtop 34% Producttop 35% Newstop 38% Techtop 39% Growthtop 47% Globaltop 50% Marketbottom 43% Fin. healthbottom 32% Funding: Raised $785M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) AI: Classified as an AI company · Product described with: ai-based, machine learning rank vs industry peers · Fliar Intelligence Index 64/100 | $785M | 9 mo ago | 27 | — | WordPressMySQLPHP+28 | 14 patents Small-molecule STING agonists and PI3Kβ inhibitors for immuno‑oncology therapeutics | 1 partnership |
| 3 | Odyssey Developer of immunotherapeutics for immunological and cancer diseases 74Funding top 12%Growth top 13%Talent top 28%Moat top 31% All 7 signals ▾Fundingtop 12% Growthtop 13% Talenttop 28% Moattop 31% Techbottom 46% Marketbottom 45% Globalbottom 39% Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $503M | 12 mo ago | 108 108 → 118 (+9%) · sector median +9% | Paul-Albert König Co-Founder and Sr. Director Biology | WordPressApple iCloud MailMicrosoft 365+22 | — | — |
| 4 | Vor Biopharma Developer of therapeutics to treat acute myeloid leukemia 78Funding top 12%Patents top 19%Innovation top 20%News top 24% All 10 signals ▾Fundingtop 12% Patentstop 19% Innovationtop 20% Newstop 24% Talenttop 27% Moattop 35% Growthtop 39% Techtop 40% Markettop 47% Globalbottom 40% Funding: Raised $477M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Patents: 188 patents matched (strict assignee match) · 154 filings since 2022 vs 34 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $477M | 6 mo ago | 133 | Siddhartha Mukherjee Founder | WordPressApple iCloud MailMySQL+29 | 188 patents Patents concentrated in health & consumer products | — |
| 5 | Agenusbio Developer of immunotherapies to treat cancer 60Funding top 20%Tech top 34%Product top 35%Market top 37% All 11 signals ▾Fundingtop 20% Techtop 34% Producttop 35% Markettop 37% Moattop 44% Partnerstop 45% Fin. healthtop 48% Growthtop 50% Newsbottom 47% Talentbottom 40% Globalbottom 39% Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly rank vs industry peers · Fliar Intelligence Index 60/100 | $441M | 12 mo ago | 533 | Garo Armen Chairman & CEO | WordPressMySQLMariaDB+19 | — | — |
| 6 | Kailera Developer of therapies for treating obesity and related conditions 60Funding top 12%Growth top 20%News top 22%Moat top 31% All 8 signals ▾Fundingtop 12% Growthtop 20% Newstop 22% Moattop 31% Techtop 40% Talentbottom 41% Globalbottom 38% Marketbottom 36% Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $400M | 8 mo ago | — | Ron Renaud Founder & CEO | DrupalApple iCloud MailPHP+27 | — | 1 internship |
| 7 | AvenCell Developer of next-generation switchable CAR T-cell immunotherapies 40Funding top 17%Moat top 42%Talent bottom 49%Market bottom 45% All 6 signals ▾Fundingtop 17% Moattop 42% Talentbottom 49% Marketbottom 45% Globalbottom 45% Techbottom 35% Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $362M | 11 mo ago | 67 | Andrew Schiermeier Chief Executive Officer | WordPressApple iCloud MailMySQL+16 | — | — |
| 8 | Parabilis Medicines Developer of peptide therapeutics for the treatment of severe diseases 55Funding top 13%Growth top 35%Moat top 37%Patents top 39% All 9 signals ▾Fundingtop 13% Growthtop 35% Moattop 37% Patentstop 39% Innovationtop 43% Globaltop 50% Talentbottom 49% Techbottom 43% Marketbottom 40% Funding: Raised $305M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $305M | 5 mo ago | — | Mathai Mammen CEO | WordPressApple iCloud MailMySQL+19 | 11 patents Design and synthesis of stapled peptide therapeutics for targeted drug delivery | — |
| 9 | Arbor Biotechnologies Provider of genomic technologies and drug discovery platform 82Patents top 15%Innovation top 17%Funding top 19%Growth top 25% All 12 signals ▾Patentstop 15% Innovationtop 17% Fundingtop 19% Growthtop 25% Producttop 25% Moattop 26% Talenttop 28% AItop 45% Markettop 47% Globalbottom 42% Techbottom 36% Newsbottom 27% Patents: 372 patents matched (strict assignee match) · 307 filings since 2022 vs 65 in 2017-21 Innovation: 372 patents (top 6% of patent-holders) · 307 filings since 2022 vs 65 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $300M | 7 mo ago | 117 117 → 102 (-13%) · sector median +9% | David Scott Co-Founder | — | 372 patents CRISPR nucleases and reverse transcriptase enzymes for genome editing platforms | 2 partnerships |
| 10 | Dewpoint Therapeutics Developer of small molecule based therapeutics 53Funding top 17%Moat top 31%Talent top 38%News top 41% All 7 signals ▾Fundingtop 17% Moattop 31% Talenttop 38% Newstop 41% Markettop 45% Globalbottom 45% Techbottom 32% Funding: Raised $287M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 53/100 | $287M | 9 mo ago | 147 | Richard Young Co-Founder | BreakdanceWordPressApple iCloud Mail+13 | — | 1 job opening |
| 11 | Minerva Neurosciences Innovating central nervous system disorder treatments with clinical expertise and patient focus 50Patents top 22%Funding top 26%Innovation top 27%Fin. health bottom 48% All 9 signals ▾Patentstop 22% Fundingtop 26% Innovationtop 27% Fin. healthbottom 48% Moatbottom 48% Globalbottom 44% Techbottom 40% Marketbottom 38% Newsbottom 38% Patents: 216 patents matched (strict assignee match) · 111 filings since 2022 vs 89 in 2017-21 Funding: Raised $247M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $247M | 7 mo ago | 10 | — | WordPressMySQLPHP+14 | 216 patents Novel CNS drug molecules and gastro-resistant oral formulations for psychiatric and metabolic disorders | — |
| 12 | Cognito Therapeutics Developer of a medical device for the treatment of Alzheimer's disease 60Talent top 22%Funding top 23%Growth top 35%Moat top 42% All 8 signals ▾Talenttop 22% Fundingtop 23% Growthtop 35% Moattop 42% Techtop 50% Marketbottom 43% Globalbottom 37% Newsbottom 21% Talent: Analyst team rating 5/5 · 3 named leaders on record Funding: Raised $227M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $227M | 3 mo ago | 42 | Ed Boyden Co-Founder | WebflowGSAPUnpkg+12 | — | — |
| 13 | Emulate Developer of in vitro models for drug development 78Funding top 15%Patents top 25%Moat top 26%Innovation top 34% All 10 signals ▾Fundingtop 15% Patentstop 25% Moattop 26% Innovationtop 34% Techtop 34% Growthtop 40% Markettop 45% AItop 45% Globalbottom 49% Newsbottom 22% Funding: Raised $225M across 10 rounds · 10 rounds over 12 yrs (0.8/yr) Patents: 479 patents matched (strict assignee match) · 170 filings since 2022 vs 309 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $225M | 8 mo ago | 103 103 → 71 (-31%) · sector median +9% | — | WordPress Block EditorWordPressApple iCloud Mail+38 | 479 patents Microfluidic organ‑on‑chip platforms for tissue modeling and drug screening | 1 job opening |
| 14 | Apnimed Developer of small molecule based therapeutics for the treatment of obstructive sleep apnea 37Funding top 14%Growth top 28%Talent top 28%Moat top 35% All 12 signals ▾Fundingtop 14% Growthtop 28% Talenttop 28% Moattop 35% Producttop 40% Techbottom 49% Globalbottom 37% Patentsbottom 34% Marketbottom 32% Innovationbottom 21% Newsbottom 18% Customersbottom 3% Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $208M | 2 mo ago | 13 | Andrew Wellman Co-Founder | WordPressApple iCloud MailMySQL+21 | 2 patents Pharmaceutical solid‑form optimization and repurposed drug therapy for sleep‑apnea treatment | 1 job opening · 1 award |
| 15 | CAMP4 Provider of a drug prediction and development tool for researchers 53Funding top 17%Growth top 37%Moat top 39%Talent top 41% All 9 signals ▾Fundingtop 17% Growthtop 37% Moattop 39% Talenttop 41% AItop 45% Marketbottom 41% Globalbottom 37% Techbottom 26% Newsbottom 20% Funding: Raised $180M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Growth: Headcount 37 → 62 (+68%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $180M | 9 mo ago | 62 62 → 62 (+0%) · sector median +9% | Josh Mandel-Brehm CEO | WordPressApple iCloud MailMicrosoft 365+13 | — | — |
| 16 | Third Arc Bio Developer of therapetics for cancer and immunological diseases 37Funding top 20%Talent top 38%Moat bottom 48%Tech bottom 47% All 7 signals ▾Fundingtop 20% Talenttop 38% Moatbottom 48% Techbottom 47% Globalbottom 36% Marketbottom 32% Newsbottom 18% Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $165M | 4 mo ago | — | Sanjaya Singh Founder & Chief Scientific Officer | GSAPReactGatsby+15 | — | — |
| 17 | Tango Therapeutics Developer of drugs for the treatment of cancer 72Funding top 21%News top 21%Growth top 24%Talent top 33% All 10 signals ▾Fundingtop 21% Newstop 21% Growthtop 24% Talenttop 33% Fin. healthtop 41% Techtop 44% Markettop 45% Partnerstop 45% Moatbottom 49% Globalbottom 37% Funding: Raised $165M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) News: 17 BI events in 12 mo (of 35 tracked, 6 types) · +240% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $165M | 7 mo ago | 140 140 → 157 (+12%) · sector median +9% | Barbara Weber Md President and CEO | DrupalPHPZURB Foundation+21 | — | — |
| 18 | Casma Therapeutics Developer of therapies for treating rare genetic disorders 40Funding top 20%Product top 30%Innovation top 38%Moat top 48% All 9 signals ▾Fundingtop 20% Producttop 30% Innovationtop 38% Moattop 48% Marketbottom 48% Growthbottom 41% Globalbottom 37% Newsbottom 22% Techbottom 21% Funding: Raised $154M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Product: 3 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 40/100 | $154M | 3 mo ago | 38 | — | — | — | — |
| 19 | Allurion Developer of Gastric Balloon device for weight loss management 50Funding top 22%Customers top 23%Product top 24%Tech top 26% All 13 signals ▾Fundingtop 22% Customerstop 23% Producttop 24% Techtop 26% Moattop 38% Markettop 40% Innovationtop 50% Talentbottom 49% Patentsbottom 42% Globalbottom 42% Newsbottom 36% Fin. healthbottom 35% Growthbottom 29% Funding: Raised $151M across 15 rounds · 15 rounds over 14 yrs (1.1/yr) Customers: Play-Store rating 4.75★ across 1,421 ratings (1 apps) · Review volume +53% in 6 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $151M | 7 mo ago | 252 | Samuel Levy Founder | DrupalApple iCloud MailPHP+31 | 38 patents Temporary intragastric implant deployment systems for minimally invasive obesity treatment | 1 award |
| 20 | Life Biosciences Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases 53Funding top 16%Growth top 28%Moat top 31%News top 43% All 7 signals ▾Fundingtop 16% Growthtop 28% Moattop 31% Newstop 43% Techtop 49% Globalbottom 39% Marketbottom 33% Funding: Raised $150M across 9 rounds · 9 rounds over 8 yrs (1.1/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $150M | 2 mo ago | 14 14 → 27 (+93%) · sector median +9% | — | WordPressMySQLPHP+20 | — | — |
| 21 | Harbinger Health AI-based cancer detection tool for providers 55Funding top 18%News top 36%Moat top 42%AI top 45% All 8 signals ▾Fundingtop 18% Newstop 36% Moattop 42% AItop 45% Talenttop 49% Techbottom 48% Marketbottom 43% Globalbottom 38% Funding: Raised $140M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) News: 2 BI events in 12 mo (of 13 tracked, 3 types) · Top themes: Leadership rank vs industry peers · Fliar Intelligence Index 55/100 | $140M | 2 mo ago | 60 | Stephen Hahn CEO | WordPressApple iCloud MailMySQL+23 | — | 2 launchs |
| 22 | Lifeward Developer of exoskeletons for individuals with spinal cord injuries and stroke rehabilitation 50Funding top 22%Product top 28%News top 30%Partners top 31% All 13 signals ▾Fundingtop 22% Producttop 28% Newstop 30% Partnerstop 31% Techtop 40% Growthtop 47% Moattop 47% Markettop 48% Patentstop 50% Talentbottom 49% Innovationbottom 48% Fin. healthbottom 40% Globalbottom 39% Funding: Raised $132M across 13 rounds · 13 rounds over 15 yrs (0.9/yr) Product: 1 published app (39 installs) · Company stage: Public rank vs industry peers · Fliar Intelligence Index 50/100 | $132M | 2 mo ago | — | Larry Jasinski CEO & MD | WordPressMySQLPHP+31 | 3 patents Pressure‑based anti‑gravity exercise and rehabilitation equipment for user weight support | 1 launch |
| 23 | Diagonal Therapeutics Developer of antibody therapeutics for the treatment of rare diseases 40Funding top 19%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 19% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 38% Funding: Raised $128M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $128M | 5 mo ago | — | Alexey Lugovskoy CEO | — | — | — |
| 24 | CREATE Medicines Developer of messenger ribonucleic acid therapies for immune cell programming 50Funding top 20%Patents top 41%Innovation top 47%Talent bottom 49% All 5 signals ▾Fundingtop 20% Patentstop 41% Innovationtop 47% Talentbottom 49% Globalbottom 35% Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $122M | 1 mo ago | — | Daniel Getts Co-Founder & CEO | — | 18 patents Therapeutic chimeric fusion proteins and gene/miRNA delivery platforms for drug development | — |
| 25 | Kala Pharmaceuticals Developer of ophthalmic treatments based on its mucosal penetrating product platform 45Funding top 22%Product top 24%Talent top 33%News top 34% All 12 signals ▾Fundingtop 22% Producttop 24% Talenttop 33% Newstop 34% Moattop 35% Patentstop 37% Innovationtop 41% Techbottom 49% Marketbottom 42% Growthbottom 42% Globalbottom 40% Fin. healthbottom 36% Funding: Raised $115M across 14 rounds · 14 rounds over 17 yrs (0.8/yr) Product: 2 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 45/100 | $115M | 3 mo ago | 34 34 → 80 (+135%) · sector median +9% | Justin Hanes Co-Founder | DrupalApple iCloud MailPHP+20 | 267 patents Mucosal and ocular drug delivery via nanoparticle and polymer-based pharmaceutical formulations | — |
| 26 | Aprea Developer of small molecule therapeutics targeting tumor suppressor proteins 40Funding top 18%Growth top 30%News top 38%Moat top 48% All 7 signals ▾Fundingtop 18% Growthtop 30% Newstop 38% Moattop 48% Globalbottom 42% Techbottom 35% Marketbottom 25% Funding: Raised $113M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $113M | 6 mo ago | 13 | — | WordPressMySQLPHP+15 | — | — |
| 27 | TRIANA Biomedicines Developer of precision medicine for the treatment of cancer 45Funding top 24%Moat top 28%Talent top 38%Patents top 41% All 9 signals ▾Fundingtop 24% Moattop 28% Talenttop 38% Patentstop 41% Newstop 43% Innovationtop 47% Techbottom 46% Marketbottom 42% Globalbottom 31% Funding: Raised $110M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 21 patents rank vs industry peers · Fliar Intelligence Index 45/100 | $110M | 6 mo ago | 38 | Jesse Chen Co-Founder & Chief Technology Officer | Cart FunctionalitySquarespace CommerceSquarespace+19 | 21 patents Patents concentrated in chemistry & materials | 2 internships |
| 28 | Stipple Bio Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target… 21Funding top 20%Talent top 38%Global bottom 48%Tech bottom 25% All 5 signals ▾Fundingtop 20% Talenttop 38% Globalbottom 48% Techbottom 25% Marketbottom 19% Funding: Raised $109M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $109M | 2 mo ago | 2 | Aaron Ring Co-Founder | WordPressMySQLPHP+11 | — | 1 partnership |
| 29 | Mediar Therapeutics Developer of antibody-based therapeutics for treating fibrosis 19Funding top 25%Moat top 48%Talent bottom 49%News bottom 42% All 6 signals ▾Fundingtop 25% Moattop 48% Talentbottom 49% Newsbottom 42% Globalbottom 39% Marketbottom 21% Funding: Raised $105M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $105M | 6 mo ago | 2 | Rahul Ballal CEO | — | — | — |
| 30 | Nocion Therapeutics Developer of therapeutics for the treatment of multiple diseases 42Funding top 23%Talent top 28%Moat top 39%Global bottom 39% All 6 signals ▾Fundingtop 23% Talenttop 28% Moattop 39% Globalbottom 39% Marketbottom 34% Newsbottom 18% Funding: Raised $104M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $104M | 6 mo ago | 15 15 → 19 (+27%) · sector median +9% | Clifford Woolf Co-Founder | — | — | — |
| 31 | Atavistik Developer of allosteric therapeutics for precision oncology and rare diseases 50Funding top 19%Talent top 28%Moat top 31%Market bottom 42% All 6 signals ▾Fundingtop 19% Talenttop 28% Moattop 31% Marketbottom 42% Globalbottom 36% Newsbottom 33% Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 3 mo ago | 33 | Ralph DeBerardinis Co-Founder | — | — | — |
| 32 | TetraScience Provider of a cloud-based data platform for life science industry 40Funding top 21%Growth top 26%Moat top 35%Tech top 50% All 9 signals ▾Fundingtop 21% Growthtop 26% Moattop 35% Techtop 50% Newsbottom 47% Globalbottom 39% Marketbottom 38% Patentsbottom 25% Innovationbottom 22% Funding: Raised $99.2M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Growth: Headcount 13 → 30 (+131%) across vintages · Web rank 5,000,000 → 10,000,000 YoY rank vs industry peers · Fliar Intelligence Index 40/100 | $99M | 4 mo ago | 30 | — | WebflowApple iCloud MailGoogle Workspace+21 | 4 patents Real-time monitoring and feedback control systems for industrial tools and equipment | 1 job opening |
| 33 | Karyopharm Biopharmaceutical company focused on developing and commercializing innovative cancer therapies 69Funding top 17%News top 26%Market top 32%Tech top 34% All 9 signals ▾Fundingtop 17% Newstop 26% Markettop 32% Techtop 34% Moattop 42% Fin. healthtop 43% Talenttop 45% Growthbottom 49% Globalbottom 49% Funding: Raised $98.4M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) News: 30 BI events in 12 mo (of 119 tracked, 8 types) · +114% YoY rank vs industry peers · Fliar Intelligence Index 69/100 | $98M | 2 mo ago | 325 325 → 320 (-2%) · sector median +9% | Michael Kauffman Cofounder | WordPressApple iCloud MailMySQL+27 | — | — |
| 34 | Solid Biosciences Developer of gene therapy platform for Duchenne muscular dystrophy 53Patents top 20%Funding top 24%Innovation top 31%Tech top 33% All 10 signals ▾Patentstop 20% Fundingtop 24% Innovationtop 31% Techtop 33% Moattop 38% Newstop 48% Marketbottom 49% Growthbottom 44% Globalbottom 42% Fin. healthbottom 32% Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $92M | 3 mo ago | 101 | — | WordPressApple iCloud MailMySQL+22 | 60 patents AAV vector manufacturing and formulation for cardiac gene therapies | — |
| 35 | AcuityMD Platform offering CRM software to the medical industry 53Funding top 18%News top 25%Talent top 28%Growth top 35% All 10 signals ▾Fundingtop 18% Newstop 25% Talenttop 28% Growthtop 35% Producttop 36% Moattop 39% Techtop 48% Marketbottom 42% Innovationbottom 37% Globalbottom 34% Funding: Raised $83.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 4 BI events in 12 mo (of 11 tracked, 3 types) · Top themes: Funding, New product rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | 48 | Michael Monovoukas Co-Founder & CEO | WebflowApple iCloud MailGoogle Workspace+20 | — | — |
| 36 | Crossbow Developer of antibody therapies for cancer treatment 42Funding top 21%Moat top 36%News top 38%Talent top 38% All 8 signals ▾Fundingtop 21% Moattop 36% Newstop 38% Talenttop 38% Innovationtop 48% Patentsbottom 49% Globalbottom 39% Marketbottom 35% Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $80M | 3 mo ago | 24 | Geraldine Paulus Co-Founder | — | 21 patents High‑precision MEMS inertial sensors and power‑efficient wireless tracking technologies | — |
| 37 | Corsera Health Developer of technology predicting and preventing cardiovascular disease before it begins 72Funding top 24%Talent top 28%AI top 45%Global bottom 48% All 4 signals ▾Fundingtop 24% Talenttop 28% AItop 45% Globalbottom 48% Funding: Raised $80.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $80M | 5 mo ago | — | Chris Cox Co-Founder | — | — | — |
| 38 | Miach Orthopaedics Developer of surgical implants for connective tissue repair 64Funding top 23%Talent top 28%Patents top 32%Moat top 32% All 10 signals ▾Fundingtop 23% Talenttop 28% Patentstop 32% Moattop 32% Growthtop 35% Innovationtop 39% Techtop 48% Marketbottom 46% Globalbottom 42% Newsbottom 22% Funding: Raised $72.5M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) Talent: Analyst team rating 5/5 · 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 64/100 | $72M | 1 mo ago | 46 | Martha Murray Founder | WordPressMySQLPHP+21 | 33 patents Injectable collagen biomaterials for orthopedic tissue repair and regeneration | — |
| 39 | Kinaset Therapeutics Developer of therapeutics to treat asthma 24Funding top 26%Talent top 28%Moat top 39%Global bottom 38% All 6 signals ▾Fundingtop 26% Talenttop 28% Moattop 39% Globalbottom 38% Marketbottom 26% Techbottom 26% Funding: Raised $68.5M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 24/100 | $68M | 5 mo ago | 10 | Frazer Morgan Co-Founder | Squarespace CommerceSquarespaceStimulus+9 | — | — |
| 40 | Terrestrial Developer of a microarray patch platform for therapeutic delivery 42Funding top 23%Talent bottom 49%Global bottom 33% All 3 signals ▾Fundingtop 23% Talentbottom 49% Globalbottom 33% Funding: Raised $57.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 42/100 | $57M | 3 mo ago | — | Kathryn Kosuda Co-Founder & CSO | — | — | — |
| 41 | Consano Bio Developer of biologic therapeutic engineered for orthopedic conditions treatment 35Funding top 28%Talent bottom 49%Global bottom 25% All 3 signals ▾Fundingtop 28% Talentbottom 49% Globalbottom 25% Funding: Raised $51.7M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 35/100 | $52M | 3 mo ago | — | Andrew Hall CEO | — | — | — |
| 42 | Metaphore Provider of machine language and computational platform for drug discovery 42Funding top 23%Talent top 28%Moat top 42%AI top 45% All 7 signals ▾Fundingtop 23% Talenttop 28% Moattop 42% AItop 45% Globalbottom 36% Techbottom 35% Marketbottom 31% Funding: Raised $50.0M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $50M | 2 mo ago | 30 | Noubar Afeyan Co-Founder | WebflowMicrosoft 365jQuery+4 | — | — |
| 43 | Stellular Bio Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells 37Funding top 28%Talent top 28%Moat bottom 38%Global bottom 37% All 5 signals ▾Fundingtop 28% Talenttop 28% Moatbottom 38% Globalbottom 37% Marketbottom 32% Funding: Raised $44.5M across 9 rounds · 9 rounds over 10 yrs (0.9/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $44M | 4 mo ago | 12 | Joseph Italiano Co-Founder | — | — | — |
| 44 | Kytopen Developer of gene delivery systems for cell therapy 50Funding top 21%Talent top 28%Moat top 32%Patents top 33% All 8 signals ▾Fundingtop 21% Talenttop 28% Moattop 32% Patentstop 33% Innovationtop 36% Globalbottom 40% Marketbottom 28% Newsbottom 22% Funding: Raised $43.1M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $43M | 2 mo ago | 12 12 → 27 (+125%) · sector median +9% | Cullen Buie Co-Founder | — | 31 patents Automated electro‑mechanical transfection systems for gene and cell delivery | — |
| 45 | Quiver Bioscience Developer of transformational medicines for neurological disorders 67Talent top 28%Funding top 31%AI top 35%Market top 50% All 5 signals ▾Talenttop 28% Fundingtop 31% AItop 35% Markettop 50% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $28.9M across 16 rounds · 16 rounds over 8 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $29M | 2 mo ago | 48 | Paul Roma Co-Founder | — | — | — |
| 46 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 1 mo ago | 51 51 → 39 (-24%) · sector median +9% | — | WordPress Block EditorWordPressMySQL+15 | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 47 | General Oncology Developer of treatments for solid metastatic cancers and blood cancers 42Funding top 41%Patents top 42%Talent top 45%Innovation top 48% All 6 signals ▾Fundingtop 41% Patentstop 42% Talenttop 45% Innovationtop 48% Globalbottom 43% Techbottom 24% Funding: Raised $21.7M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Patents: 26 patents matched (strict assignee match) · 17 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $22M | 2 mo ago | — | Arnold Glazier Founder | WordPressMySQLPHP+10 | 26 patents Combination drug regimens for treating metastatic cancer | — |
| 48 | 4D Path Developer of precision medicines for the treatment of cancer 35Talent top 28%Patents top 31%Funding top 37%Moat top 38% All 8 signals ▾Talenttop 28% Patentstop 31% Fundingtop 37% Moattop 38% Innovationtop 41% Techbottom 38% Globalbottom 37% Marketbottom 23% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $17M | 1 mo ago | 10 | Rodrigo Navarro Co-Founder & CEO & President | WordPressMySQLPHP+16 | 46 patents Lipid‑nanoparticle delivery systems for malaria vaccines and encapsulated therapeutics | 2 partnerships |
| 49 | Violet Therapeutics Developer of small molecule therapeutics targeting neurodegenerative diseases of the CNS 48Talent top 38%Funding top 39%Global bottom 48% All 3 signals ▾Talenttop 38% Fundingtop 39% Globalbottom 48% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $15.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $15M | 1 mo ago | — | Francisco Quintana Co-Founder | — | — | — |
| 50 | iSpecimen Provider of a biorepository of human clinical specimens 24News top 30%Tech top 36%Funding top 42%Partners top 45% All 9 signals ▾Newstop 30% Techtop 36% Fundingtop 42% Partnerstop 45% Growthbottom 44% Moatbottom 41% Marketbottom 38% Globalbottom 32% Fin. healthbottom 22% News: 10 BI events in 12 mo (of 51 tracked, 5 types) · +0% YoY Tech: 38 technologies across 4/8 capability areas · Cloud: Amazon Web Services, Cloudflare rank vs industry peers · Fliar Intelligence Index 24/100 | $12M | 1 mo ago | 75 | — | WordPressMySQLPHP+24 | — | — |
Top 12 Life Sciences companies in Massachusetts
#1
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees$207.8Mraised▾
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees
Developer of small molecule-based therapeutics for the treatment of obstructive sleep apnea. The company has developed a combination of Atomoxetine and Oxybutynin which reduces the obstructive sleep apnea severity. It targets the neurological control and activation of upper airway dilator muscles which improve respiration and oxygenation during sleep.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 14%Growth
top 28%Talent
top 28%Moat
top 35%Product
top 40%Tech
bottom 49%Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Conventional Debt (Apr 2026)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Talent: Analyst team rating 5/5 · 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 22k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Regional Director, Field Medical Affairs
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Conventional Debt$50M
- Mar 2026Series C$25M
- Sep 2025Conventional Debt$35M
- Apr 2025Series C$16.5M
Founders & team
Investors
Tao Capital Partners, Morningside, Alpha Wave Global, Sectoral, Columbia-Seligman Investments, NexPoint
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsDocusign
#2
Series D · Boston, Massachusetts · founded 2017 · 14 employees$150.2Mraised▾
Series D · Boston, Massachusetts · founded 2017 · 14 employees
Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases. The company is focused on targeting the biology of aging, which is the biggest risk factor for most chronic diseases. They are developing a novel partial epigenetic reprogramming platform that targets a key underlying mechanism of aging to prevent and reverse age-related diseases with significant unmet need to extend healthy human lifespan. This approach holds the promise of treating many of the most debilitating and chronic diseases. The platform builds on innovative science from world-leading researchers to partially reprogram the epigenome of aged and injured cells to restore cellular function to a younger state. This is a B2B model.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%Growth
top 28%Moat
top 31%News
top 43%Tech
top 49%Global
bottom 39%Funding: Raised $150M across 9 rounds · 9 rounds over 8 yrs (1.1/yr) · Last round Series D (Apr 2026)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 13k LinkedIn followers
Funding rounds
- Apr 2026Series D$80M
- Nov 2025Series C$31M
- Jan 2022Series C$82M
- Jun 2020Series B$18.2M
Investors
Alpha Wave Global, The Longevity Fund, National Science Foundation, Abundance Partners, Wynwood Projects, Globalive Capital
Tech stack
CloudflareCloudflare Bot ManagementCookieyesGodaddyGoogle AnalyticsGoogle Hosted Libraries
#3
Series C · Cambridge, Massachusetts · founded 2016 · 42 employees$227Mraised▾
Series C · Cambridge, Massachusetts · founded 2016 · 42 employees
Developer of a medical device for the treatment of Alzheimer's disease. The device uses gamma stimulation which helps in reactivating the immune system of the brain. It results in the reduction of amyloid plaques and tau tangles which are typical hallmarks of the disease.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Talent
top 22%Funding
top 23%Growth
top 35%Moat
top 42%Tech
top 50%Market
bottom 43%Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $227M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Series C (Mar 2026)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 15k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. Ochsner Health) announced in 12 mo
Funding rounds
- Mar 2026Series C$105M
- Mar 2025Series C$196.3M
- Jun 2024Series B$10.2M
- Jun 2022Series B$108.8M
Founders & team
Investors
Morningside, FoundersX Ventures, Alzheimer's Drug Discovery, LIfT Biosciences, IAG Capital Partners, WS Investment Company
Tech stack
CdnjsCloudflareCraft CmsFacebook PixelGoogle AnalyticsGoogle Tag Manager
#4
Series B · Cambridge, Massachusetts · founded 2019$122Mraised▾
Series B · Cambridge, Massachusetts · founded 2019
Developer of messenger ribonucleic acid therapies for immune cell programming. These therapies utilize lipid nanoparticle delivery systems to modify immune cells directly within the body. The technology targets specific cell types to address conditions related to oncology and autoimmunity. The approach focuses on the expression of chimeric antigen receptors to facilitate immune responses against disease targets.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 20%Patents
top 41%Innovation
top 47%Talent
bottom 49%Global
bottom 35%Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (May 2026)
Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Innovation: 18 patents (top 74% of patent-holders) · 17 filings since 2022 vs 1 in 2017-21
Funding rounds
- May 2026Series B$122M
Founders & team
Investors
Newpath Partners, Hatteras Venture Partners, Arch Venture Partners, Alexandria Venture Investments
#5
Public · Marlborough, Massachusetts · founded 2001$131.6Mraised▾
Public · Marlborough, Massachusetts · founded 2001
Developer of exoskeletons for individuals with spinal cord injuries and stroke rehabilitation. The company offerings include the rewalk personal exoskeleton, restore exo-suit, and myocycle FES systems for rehabilitation, recovery, and more to address physical disability.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 22%Product
top 28%News
top 30%Partners
top 31%Tech
top 40%Growth
top 47%Funding: Raised $132M across 13 rounds · 13 rounds over 15 yrs (0.9/yr) · Last round Post IPO (Mar 2026)
Product: 1 published app (39 installs) · Company stage: Public
News: 10 BI events in 12 mo (of 23 tracked, 6 types) · -9% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Oramed Pharmaceuticals Inc.) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$20M
- Jan 2025Post IPO$5M
- Feb 2021Post IPO$40M
- Dec 2020Post IPO$8M
Founders & team
Investors
Proseed Venture Capital Fund, Kreos Capital, Yaskawa, Shavit Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#6
Series B · Cambridge, Massachusetts · founded 2008 · 60 employees$140Mraised▾
Series B · Cambridge, Massachusetts · founded 2008 · 60 employees
AI-based cancer detection tool for providers. The company has developed a blood test detection tool that enables professionals to analyze and detect early cancers.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 18%News
top 36%Moat
top 42%AI
top 45%Talent
top 49%Tech
bottom 48%Funding: Raised $140M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Apr 2026)
News: 2 BI events in 12 mo (of 13 tracked, 3 types) · Top themes: Leadership
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 8k LinkedIn followers
Activity (LinkedIn): 2 product launches announced in 12 mo
Funding rounds
- Apr 2026Series B$100M
- Sep 2023Series B$140M
- 2021Series A$50M
Founders & team
Investors
Flagship Pioneering, Pictet Group, Partners Investment, Venture Catalysts, M&G, Camillus LifeSciences
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCore-JsGoogle AnalyticsGoogle Font Api
#7
Public · Cambridge, Massachusetts · founded 2019 · 133 employees$477.1Mraised▾
Public · Cambridge, Massachusetts · founded 2019 · 133 employees
Developer of therapeutics to treat acute myeloid leukemia. The company has developed cancer therapeutics using engineered hematopoietic stem cells (eHSC). The company's lead candidate includes VOR33 which targets CD33 protein in cancer patients to treat acute myeloid leukemia (AML).
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Funding
top 12%Patents
top 19%Innovation
top 20%News
top 24%Talent
top 27%Moat
top 35%Funding: Raised $477M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Post IPO (Dec 2025)
Patents: 188 patents matched (strict assignee match) · 154 filings since 2022 vs 34 in 2017-21 · Latest publication 2026
Innovation: 188 patents (top 13% of patent-holders) · 154 filings since 2022 vs 34 in 2017-21
Funding rounds
- Dec 2025Post IPO$150M
- Jun 2025Post IPO$175M
- Jul 2020Series B$110.1M
- Feb 2019Series A$42M
Founders & team
Investors
RA Capital Management, Forbion, Venrock, Caligan Partners, NEXTBio, Mingxin Capital
Tech stack
AddtoanyAddtoany Share ButtonsApple Icloud MailCloudflareCloudflare Bot ManagementCookiebot
#8
Series B · Boston, Massachusetts · founded 2016 · 46 employees$72.5Mraised▾
Series B · Boston, Massachusetts · founded 2016 · 46 employees
Miach Orthopaedics is developing bio-engineered surgical implants for connective tissue repair. The company has developed a BEAR implant which is a proprietary bio-engineered sponge designed as a bridging scaffold to facilitate healing of the torn ACL (anterior cruciate ligament).
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 23%Talent
top 28%Patents
top 32%Moat
top 32%Growth
top 35%Innovation
top 39%Funding: Raised $72.5M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) · Last round Series B (May 2026)
Talent: Analyst team rating 5/5 · 2 named leaders on record · 2 C-suite/founder profiles curated
Patents: 33 patents matched (strict assignee match) · 33 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 9k LinkedIn followers
Funding rounds
- May 2026Series B$6.5M
- Oct 2025Conventional Debt$7.5M
- Apr 2024Series B$20M
- Jan 2023Series B$30M
Founders & team
Investors
SVB, Sectoral, Endeavour Vision, Amzak Health, Smith+Nephew, NFLPA
Tech stack
CloudflareCloudflare Bot ManagementCore-JsCrazy EggFacebook PixelFancybox
#9
Series C · Cambridge, Massachusetts · founded 2017 · 38 employees$154.5Mraised▾
Series C · Cambridge, Massachusetts · founded 2017 · 38 employees
Casma Therapeutics is developing therapies for treating rare genetic disorders. They are focused on autophagy of rare genetic diseases which helps in restoring cellular balance and reversing the course of the disease. The technology enables initiation, the formation of the autophagosome, fusion with lysosomes, and lysosomal biogenesis.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 20%Product
top 30%Innovation
top 38%Moat
top 48%Market
bottom 48%Growth
bottom 41%Funding: Raised $154M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round Grant (prize money) (Mar 2026)
Product: 3 distinct product lines · Company stage: Series C
Innovation: 3 product lines
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Mar 2026Grant (prize money)$7.6M
- Nov 2022Series C$46M
- Sep 2020Series B$50M
- May 2018Series A$58.5M
Investors
The Column Group, Eventide Funds, Schroders Capital, Third Rock Ventures, Amgen, Astellas Venture Management
Tech stack
WordpressMysqlPhpNginxWp Engine
#10
XtalPi 🦄Public · Cambridge, Massachusetts · founded 2014 · 27 employees$784.8Mraised▾
XtalPi 🦄
Public · Cambridge, Massachusetts · founded 2014 · 27 employees
XtalPi has developed a proprietary technology FACES(Fast Accurate Crystalline Engineering System), which is a cloud-based computing system to predict the crystal structure which will identify polymorphs of the compound. The company's algorithms are integrated with the Amazon Web Service (AWS) high-performance computing (HPC) resources in the cloud. The team claims to have a strong background in quantum physics and machine learning. It provides services to pharmaceutical companies at various stages of drug development. The company has deployed its technology to develop an Intelligent Digital Drug Discovery and Development (ID4) platform to improve the efficiency, accuracy, and success rate of drug discovery.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 18%AI
top 26%Talent
top 28%Patents
top 31%Moat
top 31%Innovation
top 34%Funding: Raised $785M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) · Last round Post IPO (Sep 2025)
AI: Classified as an AI company · Product described with: ai-based, machine learning
Talent: Analyst team rating 4/5
Audience (LinkedIn): 18k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. OpenEye, Cadence Molecular Sciences) announced in 12 mo
Funding rounds
- Sep 2025Post IPO$268M
- Feb 2025Post IPO$268.4M
- Aug 2021Series D$400M
- Sep 2020Series C$318.8M
Investors
Tencent, Frees Fund, Zhen Fund, Renren, SoftBank Vision Fund, People's Insurance Company of China
Tech stack
Animate.CssBootstrapCdnjsCloudflareCloudflare Bot ManagementCore-Js
#11
Public · Newton, Massachusetts · founded 2008 · 325 employees$98.4Mraised▾
Public · Newton, Massachusetts · founded 2008 · 325 employees
Biopharmaceutical company focused on developing and commercializing innovative cancer therapies. It leverage proprietary scientific platforms to target key mechanisms of disease and address unmet needs in oncology through clinical research and drug development programs. It focuses on addressing complex cancers by investigating innovative mechanisms of action designed to disrupt disease progression at the cellular level. Its scientific approach is built around proprietary technology platforms aimed at modulating key biological processes involved in cancer development and survival.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Funding
top 17%News
top 26%Market
top 32%Tech
top 34%Moat
top 42%Fin. health
top 43%Funding: Raised $98.4M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) · Last round Post IPO (Mar 2026)
News: 30 BI events in 12 mo (of 119 tracked, 8 types) · +114% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Market: 325 employees (top 5% of Life Sciences) · Revenue ~$146M · ~2% of tracked Oncology revenue (20 cos, FY2026)
Audience (LinkedIn): 38k LinkedIn followers — 2.9% of this cohort's audience
Funding rounds
- Mar 2026Post IPO$30M
- Oct 2025Post IPO$8.8M
- Dec 2022Post IPO$165M
- Oct 2018Post IPO$22.5M
Founders & team
Investors
Foresite Capital, New Leaf Venture Partners, Delphi Ventures, Adage Capital Management, Armistice Capital, HealthCor Management
Tech stack
AosApple Icloud MailAutoptimizeBootstrapCdnjsCloudflare
#12
Series C · Boston, Massachusetts · founded 2018 · 48 employees$83Mraised▾
Series C · Boston, Massachusetts · founded 2018 · 48 employees
Platform offering CRM software to the medical industry. The platform enables members to personalize customer engagement, identify and quantify opportunities, forecast sales accurately, understand the value of the sales pipeline, empower the sales team, track new launches, understand product adoption and market penetration.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 18%News
top 25%Talent
top 28%Growth
top 35%Product
top 36%Moat
top 39%Funding: Raised $83.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Apr 2026)
News: 4 BI events in 12 mo (of 11 tracked, 3 types) · Top themes: Funding, New product
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 15k LinkedIn followers
Funding rounds
- Apr 2026Series C$80M
- Jun 2024Series B$45M
- May 2022Series A$31M
- May 2021Series A$7M
Founders & team
Investors
Iconiq Capital, Atreides Management, StepStone Group, Redpoint Ventures, Benchmark, Artisanal Ventures
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsFacebook Pixel
Funding & investor landscape
$89.6Btotal disclosed funding
1,305companies funded
4,999disclosed rounds
23rounds last 90 days
Most active investors
Notable founders
Andrew Wellman
Co-Founder · Apnimed
Lawrence Miller
Co-Founder · Apnimed
Ed Boyden
Co-Founder · Cognito Therapeutics
Li-Huei Tsai
Co-Founder · Cognito Therapeutics
Daniel Getts
Co-Founder & CEO · CREATE Medicines
Larry Jasinski
CEO & MD · Lifeward
Stephen Hahn
CEO · Harbinger Health
Siddhartha Mukherjee
Founder · Vor Biopharma
Robert Ang
President and CEO · Vor Biopharma
Martha Murray
Founder · Miach Orthopaedics
Patrick McBrayer
President & CEO · Miach Orthopaedics
Michael Kauffman
Cofounder · Karyopharm
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN MASSACHUSETTS · Health & Bio
How research on Biotechnology in Massachusetts is moving
A read on the academic research around Biotechnology in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 169 papers.
MGH, MIT, and UMass Chan lead Massachusetts biotech research, focusing optimistically on RNA interference, CRISPR, and biosensing, with breakthroughs dominating over concerns.
169 papers · stance +0.51 · 51% breakthrough · 18% concern
top institutions
- Massachusetts General Hospital62
- Massachusetts Institute of Technology58
- University of Massachusetts Chan Medical School20
- University of Massachusetts Amherst18
- University of Massachusetts Boston7
leading researchers
David Julian McClements · Michael R. Hamblin · Ying‐Ying Huang · Aaron Chen · Allan S. Myerson · Alper James Alcaraz
prism intelligence · tone & topics
92% positive · 3% critical tone
PharmaceuticalsMedical ResearchHealthGeneticsClinical TrialsBiology
▲
Breakthroughs73 · 43%
▼ 50%→35% share
▼0.7× share momentum388 median citations40% since 2021mostly empirical
Messenger RNA breakthrough research is rising — papers tripled from 1 to 3 despite Breakthroughs segment share falling 50%→35%.
rising sub-themes (early→recent)
- Messenger RNA1→3
- Transcription (linguistics)3→4
Landmark Comprehensive molecular profiling of lung adenocarcinoma · 5,754 cites
◆
Advancements44 · 26%
▲ 26%→28% share
▲1.1× share momentum1 median citations52% since 2021mostly empirical
In vivo research dominates Advancements, driving segment share growth from 26%→28% across 169 Massachusetts biotech papers.
rising sub-themes (early→recent)
- In vivo10
- Biodistribution3
- Sustainability2
- Population2
- Cancer research2
Landmark Fear Extinction as a Model for Translational Neuroscience: Ten Years of Progress · 1,441 cites
▼
Concerns25 · 15%
▲ 11%→16% share
▲1.5× share momentum2 median citations56% since 2021mostly reviews
Food industry and biochemical engineering concerns are intensifying — each reaching 3 papers as Concerns segment share climbed 11%→16%.
rising sub-themes (early→recent)
- Food industry3
- Biochemical engineering3
- Food science2
- Glioma2
- Synthetic biology2
Landmark Genomic responses in mouse models poorly mimic human inflammatory diseases · 2,962 cites
Common questions
How many Life Sciences companies are there in Massachusetts, United States?
Radar tracks 2066 indexable Life Sciences companies headquartered in Massachusetts, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Massachusetts, United States?
The Life Sciences companies in Massachusetts, United States on this list have raised a combined $89.6B in disclosed equity funding across 1305 funded companies.
Which is the highest-funded Life Sciences company in Massachusetts, United States?
Moderna is the highest-funded Life Sciences company in Massachusetts, United States, with $2.8B in disclosed equity funding.
How many Life Sciences companies in Massachusetts, United States are funded?
1305 of the 2066 Life Sciences companies in Massachusetts, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Massachusetts, United States?
10 Life Sciences companies in Massachusetts, United States on this list are valued at $1B or more.
Who are the top investors in Massachusetts, United States Life Sciences companies?
The most active investors in Massachusetts, United States Life Sciences companies on this list include HHS, MassChallenge, RA Capital Management, Atlas Venture, Polaris Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.